Fibroblast Growth Factor (FGF)-10 promotes the proliferation and survival of murine hepatoblasts during early stages of hepatogenesis through a Wnt-β-catenin dependent pathway. To determine the mechanism by which this occurs, we expanded primary culture of hepatoblasts enriched for progenitor markers CD133 and CD49f from embryonic day (E) 12.5 fetal liver and an established tumor initiating stem cell line from Mat1a−/− livers in media conditioned with recombinant (r) FGF10 or rFGF7. FGF Receptor (R) activation resulted in the downstream activation of MAPK, PI3K-AKT, and β-catenin pathways, as well as cellular proliferation. Additionally, increased levels of nuclear β-catenin phosphorylated at Serine-552 in cultured primary hepatoblasts, Mat1a−/− cells, and also in ex vivo embryonic liver explants indicate AKT-dependent activation of β-catenin downstream of FGFR activation; conversely, the addition of AKT inhibitor Ly294002 completely abrogated β-catenin activation. FGFR activation-induced cell proliferation and survival were also inhibited by the compound ICG-001, a small molecule inhibitor of β-catenin-CREB Binding Protein (CBP) in hepatoblasts, further indicating a CBP-dependent regulatory mechanism of β-catenin activity.
Conclusion: FGF signaling regulates the proliferation and survival of embryonic and transformed progenitor cells in part through AKT-mediated activation of β-catenin and downstream interaction with the transcriptional co-activator CBP.
Citation: Mavila N, James D, Utley S, Cu N, Coblens O, Mak K, et al. (2012) Fibroblast Growth Factor Receptor-Mediated Activation of AKT-β-Catenin-CBP Pathway Regulates Survival and Proliferation of Murine Hepatoblasts and Hepatic Tumor Initiating Stem Cells. PLoS ONE 7(11): e50401. doi:10.1371/journal.pone.0050401
Editor: Saverio Bellusci, Children‚s Hospital Los Angeles, United States of America
Received: August 15, 2012; Accepted: October 19, 2012; Published: November 30, 2012
Copyright: © 2012 Mavila et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by in part by the National Institutes of Health Grants K08 AAA01690 (to KW), the American College of Surgeons Franklin Martin Award (to KW), NIH HL073722 (to MK), USC Norris Comprehensive Cancer Center Support Grant P30 CA014089 (to MK), American Cancer Society, MGO-116519 (to CBR), and The Penn State Hershey Four Diamonds Fund (to CBR) and the California Institute for Regenerative Medicine Bridges to Stem Cell Research Award (to KM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: MK owns equity in Prism Pharmaceuticals which is developing a CBP/β-catenin antagonist. Other authors have nothing to report. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Despite progress in characterizing the physiology of hepatic progenitor/stem cells, numerous aspects of signaling pathways regulating these progenitor/stem cells remain undefined. During embryogenesis, hepatic bud formation is induced from the foregut endoderm via instructive Fibroblast Growth Factor (FGF) signaling from adjacent mesenchyme of the developing heart and septum transversum –. At different stages of fetal and postnatal life, the population of progenitor cells, termed hepatoblasts, which likely represent a heterogeneous mixture of precursor cells, variably express genes specific to hepatocytes (Albumin, Hnf4α), biliary epithelial cells (Cytokeratin-19) and putative stem/progenitor cell markers (Epcam, Cd133 and Cd49f) –. Under circumstances where liver regeneration via hepatocyte proliferation is impaired, there is evidence of FGF signaling activation promoting the proliferation of epithelial progenitor cells in response to liver injury . Further elucidation of these pathways could provide insight not only into repair mechanisms involving progenitor cells, but also into the biology of liver tumors such as hepatoblastoma, which are theorized to arise from clonal expansion of malignantly transformed progenitor/stem cells , .
The Fibroblast Growth Factor (FGF) family comprises 22 known ligands, which bind promiscuously and with variable specificity to four tyrosine kinase-type FGF Receptors (R), encoded by genes with multiple alternative splicing loci , . Notably FGF7 and FGF10, two key ligands involved in epithelial organogenesis and repair, exhibit greatest affinity for the FGFR2IIIb isoform over other FGFR , . FGFR activation is known to regulate the downstream mitogen-activated protein kinase (MAPK) and phospho-inositol-3-kinase (PI3K) pathways , . Calmont et al demonstrated that during the initial stages of hepatogenesis, the FGF-mediated MAPK pathway regulates endodermal cell specification with induction of hepatic genes, such as Albumin, whereas PI3K pathway activation promotes liver growth during early embryonic liver development .
The β-catenin pathway is an evolutionarily well-conserved signaling pathway essential to normal cellular processes such as proliferation, survival, and differentiation; it is also involved in self-renewal of progenitor cell populations during embryogenesis, tissue regeneration and repair –. The canonical pathway involves binding of the Wingless/Integrated (Wnt) ligand to the Frizzled receptor. Via a series of intermediate steps, β-catenin is activated and released from the Glycogen Synthase Kinase-3β (GSK3β)/Axin/Adenomatous Polyposis Coli (APC) complex prior to entry into the nucleus. Within the nucleus, β-catenin binds to TCF/LEF transcription factors and regulates expression of various downstream genes. Direct phosphorylation of β-catenin at Serine-552 by AKT leads to expression of a series of anti-apoptotic and cell survival genes , .
β-catenin activity is also regulated through interaction with two nuclear transcriptional co-activators: Cyclic AMP responsive element binding protein (CBP) and its highly related paralog p300. Both CBP and p300 are transcriptional co-activator proteins that can acetylate histones and non-histone proteins such as β-catenin –. Both proteins regulate gene transcription through protein-protein interactions with transcription factors and chromatin-remodeling complexes . β-catenin interacts with CBP to promote survival and proliferation of embryonic and somatic stem cells, whereas its interaction with p300 promotes the initiation of differentiation of stem cells , . CBP is also required for self-renewal of hematopoietic stem cells, while p300 regulates hematopoietic differentiation , . Additionally, TCF/β-catenin/CBP-mediated transcription decreases the rate of neuronal progenitor cell differentiation, whereas β-catenin interaction with p300 induces differentiation .
During early hepatogenesis around E10.5, Fgf10 is expressed by mesenchymal cells within the adjacent septum transversum and thereafter, by fetal hepatic stellate cells. FGF10 induces downstream activation of β-catenin in hepatoblasts likely through FGFR2IIIb activation . However, the mechanism by which FGFR2IIIb activates β-catenin and regulates the survival of hepatic progenitor/stem cells is not clear.
In the present study, we utilize in vitro culture techniques of whole mount embryonic liver, primary hepatoblasts and tumor initiating liver stem cells to characterize in greater detail the link between FGFR signaling, β-catenin activation, and progenitor cell proliferation.
Materials and Methods
C57BL6 wild-type (Jackson laboratories, Harbor, ME) mice were bred, maintained at The Saban Research Institute (TSRI) animal care facility, and handled in accordance with IACUC rules and regulations of the TSRI at Children’s Hospital Los Angeles.
The Mat1a−/− cell line, originally described by Rountree et al , was grown on standard tissue culture plates (BD Biosciences) in DMEM (Invitrogen) containing 10% Fetal Bovine Serum (FBS, Invitrogen), 100 units/100 µg/ml Penicillin/Streptomycin (Gibco, Carlsbad, CA), 1 µg/ml Insulin (Sigma-Aldrich, St. Louis, MO), 10−7 M Dexamethasone (Sigma-Aldrich), and 10 mM Nicotinamide (Sigma-Aldrich) ± 250 ng/ml Fungizone (Gibco, added only for primary culture) in a cell culture incubator maintained at 37°C and 5% CO2. Cells were trypsinized using 0.05% Trypsin-EDTA (Gibco, Carlsbard, CA) and passaged every 3–4 days.
For serum starvation, cells were washed with sterile phosphate buffered saline (PBS) twice and media was changed to DMEM containing Dexamethasone and Nicotinamide minus serum or insulin for 16 hours. FGF signaling was stimulated as described previously by growing cells in human rFGF7 or rFGF10 (R &D Systems) conditioned media at 250 ng/ml for 1 hour unless otherwise described . For loss-of-function analyses, we utilized ICG-001, a small molecule inhibitor that specifically disrupts β-catenin’s interaction with CBP  and Ly294002, a PI3K-AKT inhibitor, at the well-established dose of 10 µM concentration for the indicated time in each experiment.
Embryonic livers were isolated from E12.5 C57BL6 wild-type mouse embryos, fixed in 4% paraformaldehyde (PFA, Poly Sciences Inc., Warrington, PA) and embedded in paraffin blocks. 5 µm thick sections were used for immunofluorescence staining. De-paraffinized and antigen-retrieved tissue sections were incubated with respective primary antibodies for 16 hours at 4°C after blocking with 5% goat serum at room temperature for 10 minutes. For detection, we used secondary antibodies conjugated with Cy3, Cy5, or FITC incubated at room temperature for 1 hour. For immunocytochemistry, cells were fixed in 4% PFA for 30 minutes and washed in PBS for 5 minutes twice. The cells were permeabilized with Tris-buffered saline-Triton X-100 (0.5%) for 10 minutes and then washed in PBS for 5 minutes twice. Non-specific binding was reduced by blocking with 5% goat serum (Sigma-Aldrich) for 45 minutes at room temperature. The cells were then incubated with primary antibody for 16 hours at 4°C (see Table S1). Signals were detected by adding secondary antibody conjugated either with goat-anti-mouse Cy3/Cy5/FITC, goat anti-rat Cy3, or goat anti-rabbit Cy3/Cy5 (1∶200, Jackson Immuno Research Laboratories, West Grove, PA). Fluorescence images were acquired using Leica DM5500B immunofluorescence microscope using Leica Suite Advanced Fluorescence (LAS AF) 6000 software (Wetzlar, Germany). Phase contrast pictures were acquired using Evos Advanced Microscopy Group (AMG) transmitted light microscope coupled with Evos xl software (AMG, Bothell, Washington, USA).
Isolation of Embryonic Hepatoblasts
Embryonic liver progenitor cells were isolated from E12.5 embryos of C57BL6 mice. Isolated livers were digested with 0.03% collagenase (Sigma-Aldrich) in DMEM at 37°C for 30 minutes after which enzymatic activity was stopped using 10% FBS. Digested liver cell suspensions were then passed through 70 µm sterile filters (BD Biosciences, Franklin Lakes, NJ) to obtain single cell suspensions. Cells were spun down at 500×g for 5 minutes at 4°C. Cell depletion or selection was performed using the Milteni immuno-magnetic beads (Milteni Biotech Inc., Auburn, CA) conjugated with respective antibodies according to the manufacture’s protocol and protocols published previously . Briefly, cells were washed with ice-cold 1× Magnetic Assisted Cell Separation (MACS) buffer (PBS containing 0.5% BSA, 10 mM CaCl2, and 2 mM EDTA). CD45pos (positive) cells were depleted and CD133pos or CD49fpos cells were selected according to manufacturer protocol.
Cell viability was assessed by 0.4% Trypan blue (Gibco) staining. Approximately 1×105 or 2.5×105 viable cells were plated on Laminin-Poly-lysine coated culture slides or 3.5 cm Laminin coated culture plates (BD Biosciences). Media was changed the following day and every other day thereafter as described above. All studies on primary cultured embryonic hepatoblasts were carried out between 3–6 days after plating.
Purification of RNA and Gene Expression Analysis
2×105 cells were plated on 6-cm tissue culture plates. Cells were serum starved the following day for 16 hours in 0% FBS ± rFGF7/10 conditioned media. Total RNA was isolated by Trizol reagent (Invitrogen, Carlsbad, CA) according to manufacturer’s instructions. RNA purity was assessed by the 260/280 and 260/230 nm absorbance ratio of 2 or greater. 1 µg of total RNA was used for cDNA synthesis using the Bio-Rad iScript cDNA synthesis kit (Bio-Rad Life Science, Hercules, CA). Analysis of gene expression via Reverse-Transcription Polymerase Chain Reaction (RTPCR) was performed on Bio-Rad C1000 Thermal cycler using Taq PCR Master Mix Kit (Qiagen, Valencia, CA) and intron spanning gene specific primers (Table S2). Quantitative Real-Time PCR (qPCR) was performed using cDNA using Light-Cycler Taqman Master (Roche Applied Science, Indianapolis, IN) and probes from the Universal Probe Library (Roche Applied Science) using intron spanning, gene specific primers. Relative expression levels were calculated by Δ–Δ Ct method. Actin was used to normalize the gene expression.
Cell Proliferation and BrdU Labeling Assay
3×104 Mat1a−/− cells were plated on an eight well culture slide (BD Biosciences) and next day serum starved for 16 hours. Cells were then treated with rFGF7/10 (0–250 ng/mL culture media) for 48 hours, and total cell number was counted using a hemocytometer. For BrdU (5-bromo-2′-deoxyuridine) incorporation, 24 hours after plating, cells were serum starved for 16 hours ± CBP inhibitor, ICG-001, or PI3K-AKT inhibitor, Ly294002, and treated with rFGF7/10 and BrdU for 3 hours. In the case of embryonic HPC, 1×105 MACS-sorted CD133posCD49fpos CD45neg (negative) cells were cultured for 3 days in eight-well Laminin-poly-lysine coated culture slides. Cells were then serum starved (0.5% serum, no insulin) for 6 hours in ± ICG-001 and treated with rFGF10/7 and BrdU for 3 hours. The cells were fixed in 4% PFA for 30 minutes at room temperature, 2 N HCl for 30 minutes, and then washed twice in PBS. Cells were blocked with 5% goat serum for 45 minutes at room temperature and incubated with anti-BrdU antibody for 16 hours at 4°C. The signals were detected with Cy3 conjugated anti-mouse secondary antibody. BrdU positive cells were counted in 4–5 20× high power field images using NIH Image J software and compared with control.
Western Blot Analysis
2×105 Mat1a−/− cells were plated on 6-cm tissue culture plate and serum starved for 16 hours. FGF signaling was activated as described above. Total protein lysates were prepared from cells using Radio Immuno Precipitation Assay (RIPA) buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 0.1% Sodium deoxycholate, 1 mM EDTA, 1 mM Phenyl methyl sulphonyl fluoride (Sigma-Aldrich), Phosphatase inhibitor (PhosStop, Roche Applied Science), and protease inhibitor cocktail (Sigma-Aldrich). Nuclear proteins were isolated using NE-PER Nuclear and cytoplasmic extraction kit (Thermo Scientific). Protein concentrations were measured by Bradford’s protein assay kit (Bio-Rad Laboratories) using BSA as standard. Equal amounts of protein were separated on 8% SDS-PAGE at 100 V and transferred onto 0.4 µ thick nitrocellulose membrane for 1.5 hours at 200 mA. After blocking with 5% BSA or BLOTTO (Santa Cruz Biotechnology) prepared in Tris-buffered saline, Tween, 0.1%, (TBST) membranes were incubated with respective primary antibody diluted in blocking buffer for 16 hours at 4°C. Membranes were then washed in TBST for 10 minutes twice and incubated with horseradish peroxidase-conjugated secondary antibody. Primary and secondary antibodies used are listed in Table S1. The signals were detected using HyGLO Quick spray western blot detection reagent (Denville Scientific Inc., Metuchen, NJ). The band intensity was measured by Quantity One gel analysis software (Bio-Rad Laboratories).
Liver Explant Culture
Embryonic livers from E12.5 embryos were collected, washed in DMEM and cultured on Whatman Nucleopore Track-Etch membranes (8 µm, Whatman Inc. Florham Park, NJ) for 3 days in a cell culture incubator at 37°C ± rFGF10 and ± ICG-001. Cultured livers were fixed in 4% PFA and paraffin blocks were prepared. 5 µm sections were stained for anti-phospho-Serine-552 β-CATENIN as described earlier.
FGF Signaling in E12.5 Murine Hepatoblasts
We previously showed that E12.5 murine hepatoblasts, which exhibit FGF10-dependent β-catenin, also co-express Albumin, Cytokeratin-19, and Fgfr2IIIb . Herein, we first sought to characterize histologically the hepatoblasts in E12.5 livers. Previous studies have demonstrated that hepatic progenitor cells express a variety of cell surface markers such as CD133 (also known as Prominin) and CD49f (also known as Integrin alpha-6) –. We observed co-expression of CD133 and CD49f (Figure 1A) as well as co-expression of CD133 and CK19 (Figure 1B). We calculated that approximate 35% of cells were CD133posCD49fpos. Similarly, 35% of cells were CD133posCK19pos. We, therefore, extrapolated that approximately 35% of total liver cells are CD133posCD49fposCD19pos. Notably, subsets of CD133posCD49fpos cells also co-expressed FGFR1 or FGFR2 (Figure 1C, 1D).
(A) Immunofluorescence staining for progenitor cell markers CD133 and CD49f on E12.5 embryonic liver. Yellow cells are double positive cells. DAPI staining (blue) identifies nuclei. (B) Immunostaining of CD133 and Cytokeratin (CK19). (C) Immunostaining for CD133, CD49f and FGFR 1 and (D) FGFR2. White arrows mark triple positive cells and yellow arrows mark positive cells that do not express receptors. Data are representative of three or more independent experiments. Scale bar represents 25 µm.
To further evaluate the progenitor nature of embryonic CD133pos CD49fposcells, we enriched for these cells using Magnetic Assisted Cell Separation (MACS) methodology. We first depleted CD45pos cells to remove hematopoietic cells from the suspension of total liver cells given that the embryonic liver is a major site for extra-medullary hematopoiesis during embryogenesis; CD45 depletion consistently resulted approximately in a 50% reduction in total liver cells. We then positively selected the remaining CD45 depleted cells for CD133 and CD49f. The final cell suspensions were then plated onto Laminin-coated culture dishes, where the cells grew in monolayered colonies of small epithelioid-type cells. Beyond one week, however, many cells began to lose their oval shape and high nuclear-to-cytoplasmic ratio as well as their colony forming nature while becoming more fibroblast-like morphologically (Figure 2A). RTPCR analysis of the three-day cultured cells demonstrated expression of putative stem cell markers Cd133, Cd49f, Sca-1, α-fetoprotein as well as co-expression of hepatocyte genes Albumin and Hepatocyte nuclear factor-4α (Hnf4α), biliary epithelial gene Ck19, and a number of Fgf receptors, particularly Fgfr1IIIb and Fgfr2IIIb, which are generally expressed by epithelial cells (Figure 2B). Fgfr4, which encodes a hepatocyte-specific receptor, was also expressed. Immunofluorescence-based co-localization of HNF4α and CK19 as well as pan-CYTOKERATIN (PCK) and ALBUMIN is consistent with bipotentiality of expanded MACS-enriched cells after 6 days in culture (Figure 2C, 2D). Cd45 expression was present at day zero indicating some contamination of the plated cell population; however, Cd45 was undetectable three days later possible due to attrition of hematopoietic cells. At both zero and three days of culture, we noted expression of Fgfr1IIIc and Fgfr2IIIc, which are generally expressed by mesenchymally-derived cells. However, even by six days of culture, there was no detectable expression of mesenchymal marker DESMIN (Figure S1). All experiments with primary putative hepatoblast culture were, hereafter, completed within 6 days of plating in order to maximize epithelial progenitor cell phenotype and minimize potential epithelial mesenchymal transition.
(A) Phase contrast pictures of in vitro expanded CD133pos CD49fpos CD45neg enriched cells from E12.5 embryonic liver at different time points. Co-immunofluorescence staining for (B) HNF4α and CK19 and (C) ALBUMIN and PCK. (D) Gene expression analysis by RTPCR using RNA isolated from the MACS enriched cells before and after 3-day culture. Negative control = water and positive control = E16.5 whole embryonic cDNA. Scale bar 25 µm. (E) Proliferation indices of CD133pos CD49fpos CD45neg cells treated with rFGF7/10 for 48 hrs and pulse labeled with BrdU (n = 4, *p<0.001 compared to control). Data are representative of three or more independent experiments.
We then proceeded with the assumption that our primary embryonic liver cultures were sufficiently enriched with hepatoblasts for the purposes of this study. We further speculated that these epithelially derived cells likely express Fgfr1IIIb and Fgfr2IIIb, and, therefore, would proliferate in response to FGF7 or FGF10. We sought to determine the effect of dose escalation of rFGF7 and rFGF10 on primary hepatoblasts in vitro. We observed significant increases in proliferation index up to five-fold and six-fold with increasing concentrations of rFGF7 and rFGF10, respectively, from 0 to 250 ng/mL (Figure 2E, p<0.001). There was no evidence of inhibition across all doses with higher concentrations.
FGF Signaling Activates Downstream AKT and ERK Pathways and Promotes Cellular Proliferation in Mat1a−/− Tumor Initiating Cells
Given concerns of potential plasticity of our primary hepatoblasts in culture, we also chose to study FGF signaling activation in an established and relatively stable tumor initiating stem cell line derived from the livers of Mat1a−/− mice in order to elucidate differences and commonalities between the two cell culture models. Rountree et al., previously expanded clones of single CD133-expressing non-parenchymal cells isolated by fluorescence-activated cell sorting (FACS) from Mat1a−/− livers. The authors showed that these cells express Ck19, Albumin, Hnf4α, and α-Fetoprotein in a manner consistent with bi-potential progenitor cells. Furthermore, these cells could be passaged multiple times in vitro and transplanted subcutaneously into nude mice where they developed into small tumors of clonally expanded hepatic epithelial stem cells . To maintain our Mat1a−/− cells as phenotypically as a tumor initiating epithelial stem cell line, we further enriched for CD133 and CD49f by MACS. By immunofluorescence staining, we then demonstrated co-expression of ALBUMIN and pan-CYTOKERATIN (PCK), consistent with the previously established bipotential nature of these cells (Figure 3A). There was no observable expression of DESMIN (Figure S1C). Plated Mat1a−/− cells exhibited cuboidal, epithelial-like morphology in colonies. RTPCR gene expression analysis of Mat1a−/− cells revealed co-expression of hepatocyte specific genes (Albumin and Hnf4α), biliary specific gene (Cytokeratin-19), and stem cell/progenitor cell genes (Sca-1, Cd133, Cd49f, α-Fetoprotein). Cd45 and Fgfr4 were not detectable. Mat1a−/− cells expressed IIIb and IIIc isoforms of Fgfr1, Fgfr2, and Fgfr3, indicating potentially some degree of epithelial mesenchymal transition at the gene expression level (Figure 3B).
−/− cells. (A) Co-localization of ALBUMIN and pCK in Mat1a−/− cells. Scale bar 25 µm. (B) RTPCR analysis shows Mat1a−/− cells express putative stem gene markers and Fgfr’s. Positive (+) control E16.5 = embryonic cDNA. Data are representative of three or more independent experiments. (C) qPCR analysis shows that rFGF7/10 upregulates expression of Fgfr2IIIb (n = 3, *p<0.01). (D) Western blot analysis of time course rFGF7 treatment on Mat1a−/− cells results in the downstream phosphorylation and activation of FGF receptor, AKT, ERK and β-CATENIN (ctrl (control) = untreated cells, +ctrl = E12.5 embryonic lung). Data are representative of two independent experiments. (E) Proliferation indices for Mat1a−/− cells treated with rFGF7/10 for 48 hrs and pulse labeled with BrdU (n = 4, *p<0.001 compared to control).
We then treated these cells with rFGF7 or rFGF10. In both cases by qPCR, we observed a greater than 2-fold increase in Fgfr2IIIb mRNA level after 30 minutes of stimulation (Figure 3C, n = 3, p<0.01). Stimulation with rFGF7 increased the phosphorylation of FGFR, which recognizes all FGFR (120–130 kDa) phosphorylated at Tyrosine 653/564 (Figure 3C). Given that both FGF7 and FGF10 have much greater affinity for FGFR2IIIb than any other FGFR including FGFR1IIIb , , it is likely that the observed phosphorylation and, therefore, activation is predominantly that of FGFR2IIIb. While total FGFR cannot be determined, there was no appreciable increase in either FGFR1 or FGFR2 even though there was evidence of increased Fgfr2IIIb expression. Downstream of FGFR activation by rFGF7, we observed phosphorylation/activation of AKT (Serine 473) and ERK1/2 (Tyrosine 204), two known downstream targets of activated FGFR signaling, as well as β-CATENIN (Serine 552, Figure 3D). Moreover, treatment with either rFGF for 48 hours resulted in a significant 2- to 2.5-fold increase in proliferation of Mat1a−/− HPCs in culture (Figure 3E, p<0.001 and p<0.05).
FGF Signaling Induces AKT-dependent β-catenin Activation in Both Mat1a−/− Cells and Embryonic Hepatoblasts
FGF10 signaling induces downstream β-catenin activation leading to proliferation and enhanced survival of hepatoblasts during hepatogenesis . Given the role of PI3K signaling in liver bud growth,  we sought to determine if PI3K activation might play a role in the activation of β-catenin in hepatoblasts and Mat1a−/− cells downstream of FGFR activation. Accordingly, we analyzed CD133posCD49fpos enriched hepatoblasts derived from E12.5 liver and Mat1a−/− cells histologically for nuclear β-CATENIN phosphorylated at Serine 552 (pSer-552), the site of AKT-dependent phosphorylation and transcriptional activation . In both cases, media supplementation with either rFGF7 or rFGF10 resulted in 3- to 6-fold increases in the number of cells positive for nuclear pSer-552 β-CATENIN (Figure 4A–D, p<0.001, n = 3). Similarly, western blot analysis of the nuclear extracts from Mat1a−/− cells stimulated with rFGF10 demonstrated a ∼3-fold increase in pSer552-β-CATENIN (Figure 4E–F). The increase in pSer-552 β-CATENIN was not associated with an increase in total β-CATENIN (Figure 3D). Co-treatment of Mat1a−/− cells with rFGF7/10 and AKT inhibitor LY294002 resulted in complete abrogation of pSer-552 β-CATENIN up-regulation as well as BrdU incorporation (Figure 5A–B, p<0.001).
−/− cells. Immunofluorescence staining and quantification for pSer-552 β-CATENIN in rFGF7/10-treated MACS-enriched day-4 CD133pos CD49fpos CD45neg (A, B) and Mat1a−/− cells (C, D). Total number of pSer-552 β-CATENIN positive cells were counted in 3–4 HPF from three independent experiments each and represented as % of total cells (n = 3, *p<0.001). Scale bar 25 µm. (E, F) Western blot analysis of nuclear extracts from Mat1a−/− cells treated with rFGF10. HISTONE-H3 was used to normalize for relative nuclear protein expression levels (n = 3, *p< 0.005).
−/− cells are mediated in part through PI3K-AKT pathway. Serum-starved Mat1a−/− cells were treated with rFGF7/10 ± PI3K-AKT inhibitor LY294002 for detection and quantification of (A) pSer 552 β-CATENIN or (B) BrdU. Total and β-CATENIN/BrdU Positive cells were counted from 4–5 HPF images from 3 independent experiments and represented as relative % of control (n = 3, *p<0.001).
In vivo immuno-histologic analysis of E12.5 livers showed that the majority of the pSer-552 β-CATENIN expressing cells are co-positive for PCNA, CD133, CD49f and E-CADHERIN but not DESMIN (Figure 6A–C and Figure S2B–C). Notably, however, not all proliferating cells are pSer-552 β-CATENIN positive indicating that other pathways are involved in parallel to promote proliferation. AKT-dependent activation of β-catenin is also observed in the proliferating cells at later stages (E18.5) of embryonic liver development (Figure S2A). Similarly, ex vivo E12.5 liver explants cultured in the presence of rFGF10 demonstrated increased levels of pSer-552 β-CATENIN and proliferation (Figure 6Di–ii). These observations indicate that FGF signaling promote proliferation of hepatoblasts partly through AKT-depended β-catenin activation.
Co-staining for (A) pSer-552 β-CATENIN and PCNA, (B) pSer-552 β-CATENIN and CD133, (C) pSer-552 β-CATENIN and CD49f in vivo. (Di & ii) Co-staining for pSer-552 β-CATENIN and PCNA on E12.5 liver explant cultured for three days ± rFGF10. Data are representative of three or more independent experiments. White arrows represent single positive cells and yellow arrows show double positive cells. Scale bar = 25 µm.
FGFR Activation Promotes β-catenin-dependent Cell Cycle Progression of Embryonic Hepatoblasts and Mat1a−/− Cells through a CBP Dependent Pathway
To determine the role of the co-activator CBP in FGFR-mediated activation of β-catenin on cell cycle progression, BrdU incorporation assays were performed on CD133posCD49fpos enriched embryonic hepatoblasts and Mat1a−/− cells. FGFR activation by rFGF7 or rFGF10 for 3 hours resulted in nearly 3-fold increase in BrdU positive cells in both cell types (Figure 7A–D, n = 4, p<0.001). Co-treatment with ICG-001, an inhibitor of the CBP/catenin interaction , completely abrogated BrdU incorporation and, hence, initiation of cell proliferation induced by FGFR. FGFR activation by rFGF10 resulted in a 50% increase in the expression of Survivin, a downstream anti-apoptotic gene target of CBP-β-catenin co-activation , whereas ICG-001 co-treatment nearly completely blocked this effect (Figure 7E, p< 0.005 and p<0.05, respectively). We, therefore, conclude that FGFR-mediated activation of β-catenin-CBP pathway promotes the survival and proliferation of hepatoblasts and Mat1a−/− tumor initiating stem cells at least in part via an anti-apoptotic mechanism.
Immunodetection and quantification of BrdU positive cells in (A, B) CD133pos CD49fpos Cd45neg enriched embryonic hepatoblasts (3-day cultured) and (C, D) Mat1a−/− cells after treating with rFGF7 or rFGF10 ± β-catenin-CBP inhibitor ICG-001. Total number of BrdU positive cells were counted from 3–4 HPF from three independent experiments and represented as % of total cells (n = 3, *p<0.0001 versus control). FGF-ICG-001 was compared to respective control FGF treated experiments. (E) qPCR analysis of Survivin mRNA expression level in Mat1a−/− cells for control, DMSO control, and rFGF7/10 ± ICG-001 groups. Expression levels are normalized to Actin (n = 3, *p< 0.005, #p<0.05).
FGF signaling is required for normal hepatogenesis –. FGF1, FGF2, and FGF8, which are secreted by adjacent cardiac mesenchyme, induce liver bud formation from the foregut endoderm. Previous studies have shown that initiation of liver bud growth is dependent on AKT pathway activation . We previously reported that FGF10, secreted by embryonic hepatic stellate cells, promotes the proliferation and survival of hepatoblasts via activation of β-catenin pathway after the initial liver bud formation . In this study, we demonstrate that FGF7 and FGF10, likely through FGFR2IIIb, induce downstream β-catenin activation and its nuclear translocation in both post-liver bud embryonic hepatoblasts and Mat1a−/− tumor initiating stem cell line via AKT-dependent phosphorylation of Serine-552. We also show that FGF-induced proliferation of these hepatic progenitor/stem cells is mediated in part through the interaction of β-catenin with its co-activator CBP.
β-catenin activation is critical for normal hepatogenesis. Levels of both nuclear as well as total β-catenin increase during early liver development , . We previously showed evidence that FGF10, secreted by embryonic hepatic stellate cells of the septum transversum, induces proliferation of hepatoblasts via β-catenin activation greatest around E12.5 . In the current study, we show that FGF-dependent proliferation is mediated in part via AKT-dependent β-catenin activation in both hepatoblasts as well as in Mat1a−/–derived tumor initiating liver stem cells similar to that seen during liver bud formation . He et al demonstrated that AKT-dependent activation of β-catenin promotes self-renewal of intestinal stem/progenitor cells . Volckaert et al showed that FGF10 directly activates AKT and subsequently β-catenin via its phosphorylation at Ser-552 in lung progenitor cells to promote self-maintenance . While our data do not exclude the role of Wnt-dependent canonical stabilization of β-catenin in progenitor cells through GSK-3β/Axin/APC complex, AKT-mediated FGF-dependent activation of β-catenin clearly contributes to hepatic progenitor/stem cell self-maintenance and renewal beyond the initial stages of hepatogenesis.
CBP/β-catenin interaction appears to be critical for the self-renewal of a variety of tissue stem cells, making this complex an intriguing therapeutic target for clinical disease. Emami et al previously showed that ICG-001 selectively binds the N-terminus of CBP, without binding to the highly homologous co-activator p300, leading to inhibition of proliferation and induction of apoptosis of a colon carcinoma cell line in part via decreased expression of Cyclin D1 and Survivin, an anti-apoptotic gene . Teo et al showed that ICG-001 corrects defects in neuronal differentiation associated with familial Alzheimer’s disease-associated Presenilin-1 mutations . Henderson et al showed that administration of ICG-001 prevents and can reverse bleomycin-induced pulmonary fibrosis, in part via maintenance of the alveolar epithelium . In this study, we show that disruption of the CBP-β-catenin interaction by ICG-001 at a previously established, cytostatic dose inhibits FGF-induced proliferation of embryonic hepatoblasts as well as Mat1a−/− cells. It is conceivable that FGF-induced β-catenin activation may regulate epithelial progenitors during fibrogenic liver injury.
β-catenin pathway activation is critical for normal hepatogenesis. β-catenin pathway activation is also present in numerous cancers including hepatoblastoma , , , . Transcriptional interaction of β-catenin with its co-activators CBP and p300 must be tightly regulated during liver development to control the balance between proliferation and differentiation of stem/progenitor cells. Future studies will need to address the potential role that AKT-mediated phosphorylation of β-catenin at Ser552 plays in modulating CBP binding affinity. Taurin et al demonstrated in Cos7 cells that phosphorylation of Ser675, within the C-terminal region of β-catenin (amino acids 647–781) to which both CBP and p300 bind, promotes its interaction with CBP and enhances the proliferation of vascular smooth muscle cells , , ; the authors did not examine the effects on the p300/β-catenin interaction. Our findings demonstrate that β-catenin Ser552 phosphorylation regulates the proliferation and survival of hepatoblasts and liver tumor initiating stem cells in a CBP-dependent manner. Multiple kinase cascades can be integrated into the modulation of β-catenin co-activator interactions to control the critical decision between maintenance of potency and initiation of differentiation . It is likely that the interaction of CBP-β-catenin versus p300-β-catenin is regulated via phosphorylation of multiple residues both within the co-activators and β-catenin thereby differentially regulating stem/progenitors versus differentiated cells. Since the interaction of β-catenin with CBP promotes proliferation and maintenance of potency, while its interaction with p300 promotes the initiation of differentiation of embryonic and cancer stem cells , , β-catenin may bind predominantly to CBP during early hepatogenesis to promote the proliferation of hepatoblasts, while during the later stages of hepatogenesis, it may preferentially partner with p300 to regulate hepatocyte or biliary differentiation of hepatoblasts.
In conclusion, we show that FGF pathway-induced proliferation of embryonic hepatoblasts and Mat1a−/− liver cancer stem cells is in part dependent on AKT-mediated β-catenin activation and subsequent CBP/β-catenin driven transcription. Our observation that embryonic hepatoblasts and Mat1a−/− cells appear to be regulated in a similar fashion suggests that the FGF-AKT- β-catenin/CBP pathway is mechanistically important and likely may be conserved in other conditions of liver injury or malignancy. Precise detailing of these pathways could lead to a better understanding of the role of transcriptional co-activator regulation of β-catenin activity and also facilitate the development of future therapeutics either in the realm of stem/progenitor cell-based therapies for liver diseases or chemotherapy for hepatic malignancies.
Assessment of DESMIN staining in hepatoblasts and Mat1a−/− cells. Immunofluorescence against DESMIN and DAPI (A) before and (B) after MACS. Notably DESMIN was not detectable after MACS. (C) DESMIN was not detectable in Mat1a−/− cells. Data are representative of three or more independent experiments. Scale bar 25 µm.
Co-localization of pSer-552 β-CATENIN with in vivo embryonic liver. Co-staining for (A) PCNA and pSer-552β-CATENIN in E18.5 liver. (B) Co-staining for pSer-552β-CATENIN and epithelial marker E-CADHERIN, (C) pSer-552β-CATENIN and mesenchymal marker DESMIN in E12.5 liver. White arrows mark single positive cells. Yellow arrows and inset depict co-positive cells. Data are representative of three or more independent experiments. Scale bar 25 µm.
We thank Mark Frey, PhD and David Warburton, MD for stimulating discussions, Henri R. Ford, MD for the support on this project, and Cat Goodhue for editing assistance.
Conceived and designed the experiments: NM SU NC CBR MK KW. Performed the experiments: NM DJ SU NC OC KM. Analyzed the data: NM DJ SU NC CBR MK KW. Contributed reagents/materials/analysis tools: NM DJ SU NC CBR MK KW. Wrote the paper: NM KW.
- 1. Jung J, Zheng M, Goldfarb M, Zaret KS (1999) Initiation of mammalian liver development from endoderm by fibroblast growth factors. Science 284: 1998–2003.
- 2. Zaret KS (2001) Hepatocyte differentiation: from the endoderm and beyond. Curr Opin Genet Dev 11: 568–574.
- 3. Zaret KS (2000) Liver specification and early morphogenesis. Mech Dev 92: 83–88.
- 4. Rountree CB, Barsky L, Ge S, Zhu J, Senadheera S, et al. (2007) A CD133-expressing murine liver oval cell population with bilineage potential. Stem Cells 25: 2419–2429.
- 5. Hoppo T, Fujii H, Hirose T, Yasuchika K, Azuma H, et al. (2004) Thy1-positive mesenchymal cells promote the maturation of CD49f-positive hepatic progenitor cells in the mouse fetal liver. Hepatology 39: 1362–1370.
- 6. Laurson J, Selden C, Clements M, Mavri-Damelin D, Coward S, et al. (2007) Putative human liver progenitor cells in explanted liver. Cells Tissues Organs 186: 180–191.
- 7. Tanimizu N, Miyajima A, Mostov KE (2007) Liver progenitor cells develop cholangiocyte-type epithelial polarity in three-dimensional culture. Mol Biol Cell 18: 1472–1479.
- 8. Cardinale V, Wang Y, Carpino G, Cui CB, Gatto M, et al. (2011) Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology 54: 2159–2172.
- 9. Zhang L, Theise N, Chua M, Reid LM (2008) The stem cell niche of human livers: symmetry between development and regeneration. Hepatology 48: 1598–1607.
- 10. Hu Z, Evarts RP, Fujio K, Marsden ER, Thorgeirsson SS (1995) Expression of fibroblast growth factor receptors flg and bek during hepatic ontogenesis and regeneration in the rat. Cell Growth Differ 6: 1019–1025.
- 11. Cairo S, Armengol C, De Reynies A, Wei Y, Thomas E, et al. (2008) Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 14: 471–484.
- 12. Fiegel HC, Gluer S, Roth B, Rischewski J, von Schweinitz D, et al. (2004) Stem-like cells in human hepatoblastoma. J Histochem Cytochem 52: 1495–1501.
- 13. Bottcher RT, Niehrs C (2005) Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 26: 63–77.
- 14. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116–129.
- 15. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, et al. (2006) Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 281: 15694–15700.
- 16. Yeh BK, Igarashi M, Eliseenkova AV, Plotnikov AN, Sher I, et al. (2003) Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc Natl Acad Sci U S A 100: 2266–2271.
- 17. Calmont A, Wandzioch E, Tremblay KD, Minowada G, Kaestner KH, et al. (2006) An FGF response pathway that mediates hepatic gene induction in embryonic endoderm cells. Dev Cell 11: 339–348.
- 18. Nejak-Bowen K, Monga SP (2008) Wnt/beta-catenin signaling in hepatic organogenesis. Organogenesis 4: 92–99.
- 19. Micsenyi A, Tan X, Sneddon T, Luo JH, Michalopoulos GK, et al. (2004) Beta-catenin is temporally regulated during normal liver development. Gastroenterology 126: 1134–1146.
- 20. Lade AG, Monga SP (2011) Beta-catenin signaling in hepatic development and progenitors: which way does the WNT blow? Dev Dyn 240: 486–500.
- 21. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434: 843–850.
- 22. Sokol SY (2011) Maintaining embryonic stem cell pluripotency with Wnt signaling. Development 138: 4341–4350.
- 23. Miki T, Yasuda SY, Kahn M (2011) Wnt/beta-catenin Signaling in Embryonic Stem Cell Self-renewal and Somatic Cell Reprogramming. Stem Cell Rev.
- 24. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, et al. (2007) Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 282: 11221–11229.
- 25. Ponce DP, Yefi R, Cabello P, Maturana JL, Niechi I, et al. (2011) CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expression of survivin and enhance cell survival. Mol Cell Biochem 356: 127–132.
- 26. Wolf D, Rodova M, Miska EA, Calvet JP, Kouzarides T (2002) Acetylation of beta-catenin by CREB-binding protein (CBP). J Biol Chem 277: 25562–25567.
- 27. Levy L, Wei Y, Labalette C, Wu Y, Renard CA, et al. (2004) Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol Cell Biol 24: 3404–3414.
- 28. Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14: 1553–1577.
- 29. Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R (2000) The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. Embo J 19: 1839–1850.
- 30. Bedford DC, Kasper LH, Fukuyama T, Brindle PK (2010) Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases. Epigenetics 5: 9–15.
- 31. Teo JL, Kahn M (2010) The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators. Adv Drug Deliv Rev 62: 1149–1155.
- 32. Miyabayashi T, Teo JL, Yamamoto M, McMillan M, Nguyen C, et al. (2007) Wnt/beta-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc Natl Acad Sci U S A 104: 5668–5673.
- 33. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, et al. (2002) Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A 99: 14789–14794.
- 34. Chan WI, Hannah RL, Dawson MA, Pridans C, Foster D, et al. (2011) The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells. Mol Cell Biol 31: 5046–5060.
- 35. Teo JL, Ma H, Nguyen C, Lam C, Kahn M (2005) Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation. Proc Natl Acad Sci U S A 102: 12171–12176.
- 36. Berg T, Rountree CB, Lee L, Estrada J, Sala FG, et al. (2007) Fibroblast growth factor 10 is critical for liver growth during embryogenesis and controls hepatoblast survival via beta-catenin activation. Hepatology 46: 1187–1197.
- 37. Rountree CB, Senadheera S, Mato JM, Crooks GM, Lu SC (2008) Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology 47: 1288–1297.
- 38. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, et al. (2004) A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 101: 12682–12687.
- 39. Ma H, Nguyen C, Lee KS, Kahn M (2005) Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 24: 3619–3631.
- 40. Monga SP, Monga HK, Tan X, Mule K, Pediaditakis P, et al. (2003) Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 124: 202–216.
- 41. He XC, Yin T, Grindley JC, Tian Q, Sato T, et al. (2007) PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 39: 189–198.
- 42. Volckaert T, Dill E, Campbell A, Tiozzo C, Majka S, et al. (2011) Parabronchial smooth muscle constitutes an airway epithelial stem cell niche in the mouse lung after injury. J Clin Invest 121: 4409–4419.
- 43. Henderson WR Jr, Chi EY, Ye X, Nguyen C, Tien YT, et al. (2010) Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A 107: 14309–14314.
- 44. Thompson MD, Monga SP (2007) WNT/beta-catenin signaling in liver health and disease. Hepatology 45: 1298–1305.
- 45. Yang W, Yan HX, Chen L, Liu Q, He YQ, et al. (2008) Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 68: 4287–4295.
- 46. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO (2006) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 281: 9971–9976.
- 47. Taurin S, Sandbo N, Yau DM, Sethakorn N, Dulin NO (2008) Phosphorylation of beta-catenin by PKA promotes ATP-induced proliferation of vascular smooth muscle cells. Am J Physiol Cell Physiol 294: C1169–1174.
- 48. Kahn M (2011) Symmetric division versus asymmetric division: a tale of two coactivators. Future Med Chem 3: 1745–1763.